Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 67

Results For "NAGI"

1741 News Found

Senores receives ANDA approval for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet USP
Drug Approval | January 13, 2025

Senores receives ANDA approval for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet USP

Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate, a beta adrenoceptor blocker and hydrochlorothiazide (HCTZ), a thiazide diuretic, indicated for the treatment of hypertension, to lower blood pressure


Aragen secures $100 million investment from Quadria Capital
News | January 13, 2025

Aragen secures $100 million investment from Quadria Capital

Investment will fund expansion to meet rising demand for CRDMO services


ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe
News | January 10, 2025

ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe

According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually


Windlas Biotech’s new injectable facility receives GMP certification
News | January 10, 2025

Windlas Biotech’s new injectable facility receives GMP certification

The certification marks a new chapter in Windlas Biotech’s growth trajectory,


Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification
Drug Approval | January 09, 2025

Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification

The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024


Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments
Clinical Trials | January 09, 2025

Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments

The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life


Lilly to establish new global capability centre in Hyderabad
News | January 09, 2025

Lilly to establish new global capability centre in Hyderabad

Lilly plans to hire approximately more than 1,000 new highly-skilled team members


Biocon Biologics embarks on a three-stage strategic journey
News | January 08, 2025

Biocon Biologics embarks on a three-stage strategic journey

Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries


Cupid secures Rs. 14.91 crore order from Govt. of Tanzania for supply of male condoms
News | January 05, 2025

Cupid secures Rs. 14.91 crore order from Govt. of Tanzania for supply of male condoms

The order, part of an international framework agreement is to be executed between February to April, 2025


Godrej Agrovet launches Pride Hog feed range to boost pig health and immunity
News | January 04, 2025

Godrej Agrovet launches Pride Hog feed range to boost pig health and immunity

Brings together industry experts to discuss preventive steps to protect pigs from African swine fever and best practises for pig farm management